Drugs / AsiDNA
AsiDNA
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03579628 | Apr 2018 → Feb 2021 | — | Valerio Therapeutics | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05700669 | Feb → Oct 2023 | breast cancer, malignant epithelial tumor of ovary, prostate carcinoma | Valerio Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT05394558 | May 2022 → Sep 2023 | malignant glioma | Institut Curie | Terminated | No outcome recorded |
| Phase 1/2 | NCT04826198 | Oct 2020 → Apr 2024 | ovarian cancer | Gustave Roussy, Cancer Campus, Grand Paris | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AsiDNA | “Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously” NCT04826198 ↗4“All patients will receive a loading dose of AsiDNA intravenously” NCT05700669 ↗ |
| Known as | AsiDNATM | “Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously” NCT04826198 ↗ |
| Known as | etidaligide | “Patients will receive the IMP which is the AsiDNA (etidaligide).” NCT05394558 ↗ |
| Action | Inhibit | “AsiDNATM, a DNA Repair Inhibitor” NCT04826198 ↗ |
| Modality | Oligonucleotide (other) | “AsiDNA, a first-in-class oligonucleotide-mimicking double-stranded DNA breaks” PMID 32839491 ↗ Aug 2020 |
| Route | Intravenous | “administered intravenously” NCT03579628 ↗ |